fasturtec
sanofi winthrop industrie - rasburicaseom - hiperuricemija - svi ostali terapeutski proizvodi - liječenje i profilaksa akutnog hiperuricemija, kako bi se spriječilo zatajenje bubrega u odraslih, djece i adolescenata (u dobi od 0 do 17 godina) s hematološke zloćudne bolesti s veliku tumorsku i riziku od brzog tumorske lize ili skupljanja u početka kemoterapije.
lenalidomid alkaloid 5 mg/1 kapsula kapsula, tvrda
alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 5 mg lenalidomida
lenalidomid alkaloid 10 mg/1 kapsula kapsula, tvrda
alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 10 mg/1 kapsula - 1 kapsula, tvrda sadrži: 10 mg lenalidomida
lenalidomid alkaloid 15 mg/1 kapsula kapsula, tvrda
alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 15 mg/1 kapsula - 1 kapsula, tvrda sadrži: 15 mg lenalidomida
lenalidomid alkaloid 25 mg/1 kapsula kapsula, tvrda
alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg lenalidomida
lenalidomid alkaloid 2,5 mg/1 kapsula kapsula, tvrda
alkaloid d.o.o. sarajevo - lenalidomid - kapsula, tvrda - 2,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 2,5 mg lenalidomida
blincyto
amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
ribomustin 25 mg/1 viala prašak za koncentrat za otopinu za infuziju
clinres farmacija d.o.o. - bendamustin - prašak za koncentrat za otopinu za infuziju - 25 mg/1 viala - 1 bočica sa praškom za koncentrat za otopinu za infuziju sadrži: 25 mg bendamustin (u obliku bendamustinhidrohlorida) 25 mg (2,5 mg/ml)
ribomustin 100 mg/1 viala prašak za koncentrat za otopinu za infuziju
clinres farmacija d.o.o. - bendamustin - prašak za koncentrat za otopinu za infuziju - 100 mg/1 viala - 1 bočica sa praškom za koncentrat za otopinu za infuziju sadrži: 100 mg bendamustina (u obliku bendamustinhidrohlorida)
lenalidomid zentiva 10 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - lenalidomid - kapsula, tvrda - 10 mg - urbroj: jedna kapsula sadrži 10 mg lenalidomida